

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
19 September 2024 (19.09.2024)



(10) International Publication Number
WO 2024/192308 A3

(51) International Patent Classification:

C07K 16/28 (2006.01) A61P 13/08 (2006.01)
C07K 16/30 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2024/020035

(22) International Filing Date:

14 March 2024 (14.03.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/490,167	14 March 2023 (14.03.2023)	US
63/490,171	14 March 2023 (14.03.2023)	US
63/495,989	13 April 2023 (13.04.2023)	US
63/496,374	14 April 2023 (14.04.2023)	US
63/578,592	24 August 2023 (24.08.2023)	US

(71) Applicant: XENCOR, INC. [US/US]; 465 North Halstead Street, Suite 200, Pasadena, CA 91107 (US).

(72) Inventors: MOORE, Gregory; C/o Xencor, Inc., 465 North Halstead Street, Suite 200, Pasadena, CA 91107 (US). DAVRA, Viralkumar, Rameshkumar; C/o Xencor, Inc., 465 North Halstead Street, Suite 200, Pasadena, CA 91107 (US). NAM, Dong, Hyun; C/o Xencor, Inc., 465 North Halstead Street, Suite 200, Pasadena, CA 91107 (US). GUSTI ZENG, Veronica; C/o Xencor, Inc., 465 North Halstead Street, Suite 200, Pasadena, CA 91107 (US). HEDVAT, Michael; C/o Xencor, Inc., 465 North Halstead Street, Suite 200, Pasadena, CA 91107 (US). QI, Jing; C/o Xencor, Inc., 465 North Halstead Street, Suite 200, Pasadena, CA 91107 (US). RASHID, Rumana; C/o Xencor, Inc., 465 North Halstead Street, Suite 200, Pasadena, CA 91107 (US). ARPP, Patrick; C/o Xencor, Inc., 465 North Halstead Street, Suite 200, Pasadena, CA 91107 (US). DELGADO, Ernesto; C/o Xencor, Inc., 465 North Halstead Street, Suite 200, Pasadena, CA 91107 (US). TAN, Chaofang; C/o Xencor, Inc., 465 North Halstead Street, Suite 200, Pasadena, CA 91107 (US). BAKHIT, Charles, G.; C/o Xencor, Inc., 465 North Halstead Street, Suite 200, Pasadena, CA 91107 (US). DIAZ, Juan; C/o Xencor, Inc., 465 North Halstead Street, Suite 200, Pasadena, CA 91107 (US). PRECIADO JIMENEZ, Heather; C/o Xencor, Inc., 465 North Halstead Street, Suite 200, Pasadena, CA 91107 (US).

(74) Agent: NGUYEN, Louis-vu, T. et al.; Morgan, Lewis & Bockius, LLP, One Market, Spear Street Tower, San Francisco, CA 94105 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(88) Date of publication of the international search report:

07 November 2024 (07.11.2024)

(54) Title: ANTI-CD28 COMPOSITIONS

(57) Abstract: Provided herein are novel anti-CD28 x anti-STEAP1 and anti-CD28 x anti-CEACAM5 antibodies and methods of using such antibodies for the treatment of related cancers.

WO 2024/192308 A3